Article

Differential kynurenine pathway metabolism in highly-metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression

2020-09-16

Abstract excerpt

<title>Abstract</title> <p><bold>Background: </bold>Immunotherapy has recently been proposed as a promising treatment to stop breast cancer (BrCa) progression and metastasis. However, there has been limited success in the treatment of BrCa with immune checkpoint inhibitors. This implies that BrCa tumors have other mechanism(s) to escape immune surveillance. While the kynurenine pathway (KP) is known to be a key p...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5e62243f-0c28-5792-9539-7d92aed1fb6c
DOI: 10.21203/rs.3.rs-57673/v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Differential kynurenine pathway metabolism in highly-metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppressionDOI 10.21203/rs.3.rs-57673/v2Read

Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppressionSemantic proximity Read

Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trialsSemantic proximity Read

The Kynurenine Pathway and Cancer: Why Keep It Simple When You Can Make It ComplicatedSemantic proximity Read

Targeting the kynurenine pathway: another therapeutic opportunity in the metabolic crosstalk between cancer and immune cellsSemantic proximity Read

Immunosuppressive metabolites in tumoral immune evasion: redundancies, clinical efforts, and pathways forwardSemantic proximity Read

Bioinformatics-based analysis of amino acid metabolism-related features to predict clinical prognosis and immunotherapy response in triple-negative breast cancerSemantic proximity Read

Targeting the kynurenine pathway in gliomas: Insights into pathogenesis, therapeutic targets, and clinical advancesSemantic proximity Read

Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibitionSemantic proximity Read

Nuclear‐Localized BCKDK Facilitates Homologous Recombination Repair to Support Breast Cancer Progression and Therapy ResistanceSemantic proximity Read

Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancerSemantic proximity Read

Lysine lactylation (Kla) might be a novel therapeutic target for breast cancerSemantic proximity Read

Inhibition of UBA6 by inosine augments tumour immunogenicity and responsesSemantic proximity Read